ArticleBMC pediatrics2026
Analysis of the clinical phenotype and genotype features of 5 cases of beta-ketothiolase deficiency.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBeta-Ketothiolase deficiency (BKTD) is a rare congenital inherited metabolic disorder associated with defects in the catabolism of isoleucine. This article introduces the clinical phenotypes and genetic variation characteristics of 5 pediatric patients with BKTD.
resultsWe retrospectively analyzed the clinical manifestations, laboratory parameters and genetic testing data of 5 pediatric patients with BKTD treated at Beijing Children’s Hospital from April 2018 to October 2024. Among the 5 patients, 4 were male and 1 was female. Their ages of diagnose ranged from 6 months to 1 year and 10 months, with a median age of 9 months. The main clinical manifestations included lethargy, tachypnea, vomiting, respiratory failure, severe metabolic acidosis, and elevated ketone bodies in blood and urine after infection. The levels of 3-hydroxybutyrylcarnitine, 3-hydroxyisovalerylcarnitine, and tiglylcarnitine in the blood were elevated, reaching 2.3 to 18.1 times, 2.3 times, and 2.7 to 5.3 times the upper limits of normal, respectively. The levels of 2-methyl-3-hydroxybutyrate in urine were elevated in all 5 patients, reaching 5.3 to 80.5 times the upper limit of normal. Meanwhile, 3 patients had elevated levels of tiglylglycine and 2-methylacetoacetate in urine. Among the 5 patients, patients 1, 2, and 5 carried three previously unreported missense variations: c.439G > T (p.Val147Leu), c.193 A > T (p.Thr65Ser), and c.224 C > A (p.Ala75Asp). Patients 2 and 3 carried the splice site variation c.1163 + 5G > C and the frameshift variation c.552_555del, respectively, both of which were previously unreported. After clinical diagnosis of BKTD, the patients were given a low-protein, high-carbohydrate, low-fat diet, supplemented with L-carnitine, vitamins B1 and B2. The follow-up time ranged from 4 months to over 6 years. One patient still experienced 1 to 2 episodes of mild metabolic acidosis annually due to non-adherence to dietary management and infections, but none of the patients had severe metabolic crises.
conclusionsBKTD is a rare disease primarily caused by variations in the ACAT1 gene. The Onset triggers, symptoms, and lab results varied widely among patients. This study not only reported new genetic findings but also stressed the importance about recognizing BKTD in infants and toddlers with non-diabetic ketoacidosis. Early acute care and sustained follow-up secure better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.